Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-positive breast cancer, drawn from the whole corpus: 133 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Brain metastases in ~50% of metastatic patients.
Background: HER2-positive brain metastases, The blood-brain barrier & brain metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Which patients can skip chemotherapy entirely.
Sequencing after T-DXd: no randomised data on which HER2 ADC or TKI works after TOP1-payload failure.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Interstitial lung disease with T-DXd in curative settings, where patients would otherwise be cured.
Over-treatment: which patients need pertuzumab, a full year of antibodies, or any chemotherapy at all (PHERGain-2, response-adapted trials).
Brain metastasis prevention and whether systemic-first strategies preserve cognition.
Background: HER2-positive brain metastases, The blood-brain barrier & brain metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
HR+/HER2+ ('triple-positive') disease: optimal integration of endocrine therapy, CDK4/6 inhibitors, and HER2 blockade.
Cardiotoxicity surveillance burden versus event rates in low-risk patients.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Global access: biosimilars have widened trastuzumab access but pertuzumab, T-DM1, and T-DXd remain unavailable in much of the world.
Background: Biosimilar. Also on OnCo: Financial help · Coverage by country · HTA decisions.
HER2 heterogeneity and HER2 conversion at relapse require re-biopsy strategies or HER2 PET.
Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 62 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Phase 3 vs T-DM1 in residual disease registered (NCT06830889)
Weight loss achieved; primary iDFS endpoint not met at first analysis (presented 2025; publication pending, verify).
3-year iDFS 92.